等待开盘 09-09 09:30:00 美东时间
-0.010
-0.05%
• Apollo's assets under management surpassed one trillion dollars driven by strong performance. • The firm expanded into artificial intelligence infrastructure and mega-scale technology financing. • Annual revenue reached $31.85 billion, ranking first in the collective investments industry.
08-11 16:15
Fidus Investment Corporation (NASDAQ: FDUS) announced it will release its second quarter 2026 financial results on August 6, 2026, after market close. A conference call to discuss the results will be held on August 7, 2026, at 9:00am ET. Participants can dial (844) 808-7136 (US) or (412) 317-0534 (international) and ask to join the Fidus Investment Corporation call. A live webcast will be available at https://investor.fdus.com/news-events/events-...
07-30 20:05
今日重点评级关注:Needham:维持Immuneering"买入"评级,目标价从11美元升至18美元;富瑞:维持塞德斯医疗"买入"评级,目标价从90美元升至100美元
07-21 11:36
Keefe, Bruyette & Woods analyst Paul Johnson downgrades Fidus Investment (NASDAQ:FDUS) from Outperform to Market Perform and maintains the price target from $19.5 to $19.5.
07-20 17:46
Fidus Investment ( ($FDUS) ) just unveiled an announcement. On June 24, 2026, F...
06-25 05:17
Earnings Call Insights: Fidus Investment Corporation (FDUS) Q1 2026 Management view "Fidus' first quarter results were extremely strong from an income statement perspective with an adjusted NII of $0....
05-08 22:42
今日重点评级关注:HC Wainwright & Co.:维持FibroBiologics"买入"评级,目标价从4美元升至8美元;摩根士丹利:维持Ultragenyx药业"超配"评级,目标价从50美元升至67美元
04-17 11:27
Keefe, Bruyette & Woods analyst Ryan Lynch maintains Fidus Investment (NASDAQ:FDUS) with a Outperform and lowers the price target from $20 to $19.5.
04-16 19:57
今日重点评级关注:LUCID CAPITAL MARKETS:上调INmune Bio评级至"买入" 目标价从2美元升至9美元;Clear Street:维持MoonLake Immunotherapeutics Class A"买入"评级,目标价从45美元升至70美元
03-12 12:34